Business Context and Reporting Period
This Form 8-K, dated April 7, 2023, is filed by Chavant Capital Acquisition Corp. (Chavant) regarding its proposed business combination with Mobix Labs, Inc. (Mobix Labs). The filing details the entry into Amendment No. 1 to the Business Combination Agreement originally dated November 15, 2022. The transaction involves a merger where Mobix Labs will become a wholly-owned subsidiary of Chavant.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for Mobix Labs or Chavant. This document focuses on the structural terms of the merger agreement rather than financial performance data.
Material Changes Versus Prior Period
- Extension of Outside Date: The deadline to complete the transaction (Outside Date) has been extended from July 22, 2023, to November 22, 2023.
- Adjustment to Exchange Ratio Calculation: Securities issued by Mobix Labs after March 26, 2023, for cash (defined as "Post-March 26 Financing Securities") will be excluded from the "Company Fully Diluted Number" calculation. Consequently, the Per Share Exchange Ratio will not be reduced due to these specific issuances.
- Use of Proceeds: Mobix Labs is required to use proceeds from Post-March 26 Financing Securities for ongoing business operations or transaction expenses, subject to Chavant's consent.
Guidance, Outlook, and Risks
Outlook and Status: Chavant and Mobix Labs announced the filing of a registration statement on Form S-4 on April 10, 2023. A proxy statement/prospectus will be sent to Chavant shareholders for a vote on the transaction.
Risks and Contingencies: The filing outlines significant risks, including:
- Failure to complete the transaction in a timely manner or at all.
- Inability to satisfy conditions for consummation, such as shareholder approval or meeting minimum cash requirements following redemptions.
- Disruption to Mobix Labs' business operations and employee retention.
- Failure to commercialize semiconductor products or achieve profitability.
- Need for additional capital which may not be available on acceptable terms.
- Regulatory and geopolitical risks, including U.S./China trade tensions and supply chain issues.
Important Facts for Investor Verification
- Verify the final terms of the "Post-March 26 Financing Securities" and their impact on share dilution.
- Confirm the status of the Form S-4 registration statement and the scheduled shareholder vote date.
- Review the minimum cash amount required to close the transaction and the current redemption levels of Chavant's public shareholders.
- Assess Mobix Labs' ability to raise necessary capital and commercialize its semiconductor technology within the new timeline.
- Monitor the progress of the PIPE investment, as its failure is listed as a specific risk to the transaction.